I Im mp pl la an nt ta ab bl le e a ac cc ce es ss s s sy ys st te em m f fo or r p pr ro ol lo on ng ge ed d i in nt tr ra ap pl le eu ur ra al l i im mm mu un no ot th he er ra ap py y P. Driesen*, C. Boutin*, J.R. Viallat**, P.H. Astoul*, J.P. Vialette*, J. Pasquier** Implantable access system for prolonged intrapleural immunotherapy. P. Driesen, C. Boutin, J.R. Viallat, P.H. Astoul, J.P. Vialette, J. Pasquier. ERS Journals Ltd 1994. ABSTRACT: We describe our experience using an implantable Port-A-Cath access system for intrapleural administration of γ-interferon (γ-IFN) in malignant mesothelioma patients.Twenty nine patients, with histologically proven malignant mesotheliomas were included in this study. To avoid complications the device was implanted in a subcutaneous pocket, and the catheter was connected via a tunnel. Also, a suction drain was installed in the pocket after placement.This procedure greatly reduced the high infection rate (64%) encountered with conventional open chest tubes. Patients' tolerance was excellent and maintenance minimal.In our opinion, the Port-A-Cath system is the most suitable device for intracavitary long-term therapy of malignant pleural effusions.

No abstract